9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

 

Archive

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

Condition Cervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000316451|NCI-03-C-0243|NCI-6221|NCI-SS1PE-002 Study First Received: August 6, 2003 Last Updated: April 29, 2015 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00066651...

Continue reading

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Condition Cervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000068351|NCI-01-C-0011|NCI-6249 Study First Received: December 6, 2000 Last Updated: April 29, 2015 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00006981...

Continue reading

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Condition Adrenocortical Carcinoma|Brain and Central Nervous System Tumors|Head and Neck Cancer|Liver Cancer|Malignant Mesothelioma|Pheochromocytoma|Sarcoma Estimated Enrollment: 30 Age Group: up to 65 Years   (Child, Adult) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CAN-OTT-9401|CDR0000063892|NCI-V94-0566 Study First Received: November 1, 1999 Last Updated: July 9, 2013 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: Ottawa Regional Cancer Centre|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00002608...

Continue reading

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Condition Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Malignant Mesothelioma|Pancreatic Cancer Estimated Enrollment: 40 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: SVMC-ONC-222|CDR0000076913|NCI-V91-0075 Study First Received: November 1, 1999 Last Updated: July 9, 2013 Estimated Primary Completion Date: December 2007 Primary Outcome Measures: Clinical response (patients with evaluable disease)|Duration of response (patients with evaluable disease)|Survival (patients with evaluable disease)|Time to recurrence (patients without evaluable disease)|Survival (patients without evaluable disease) Sponsors and Collaborators: St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00002475...

Continue reading

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Condition Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|Sarcoma Estimated Enrollment: 16 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2007LS086|0712M22703 Study First Received: June 20, 2008 Last Updated: November 6, 2012 Estimated Primary Completion Date: September 2010 Primary Outcome Measures: Maximum tolerated dose of sorafenib tosylate|Disease Response|Maximum, Minimum and AUC Concentrations of Sorafenib Sponsors and Collaborators: Masonic Cancer Center, University of Minnesota Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00703638...

Continue reading

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Condition Advanced Malignant Mesothelioma|Carcinoma of the Appendix|Ovarian Sarcoma|Ovarian Stromal Cancer|Pseudomyxoma Peritonei|Recurrent Colon Cancer|Recurrent Malignant Mesothelioma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage III Colon Cancer|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage IV Colon Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Unspecified Childhood Solid Tumor, Protocol Specific Estimated Enrollment: 10 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care Study ID Numbers: CCCWFU 97110|NCI-2010-00980 Study First Received: May 13, 2010 Last Updated: January 17, 2017 Estimated Primary Completion Date: April 2011 Primary Outcome Measures: Assess feasibility of instituting an orientation program, brief follow up...

Continue reading

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Condition Cancer Estimated Enrollment: 42 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 05-002|12,158 Study First Received: September 16, 2005 Last Updated: January 15, 2016 Estimated Primary Completion Date: October 2013 Primary Outcome Measures: Time-to-progression (TTP)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS) Sponsors and Collaborators: University of Pittsburgh|Eli Lilly and Company|Genentech, Inc. Result Received: January 15, 2016 Website Link: https://ClinicalTrials.gov/show/NCT00222729...

Continue reading

Thrombin Generation and Platelet Activation in CRS/HIPEC

Condition Mesothelioma; Peritoneum|Pseudomyxoma Peritonei|Peritoneal Carcinomatosis Estimated Enrollment: 27 Age Group: up to 80 Years   (Child, Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: B37120154199 Study First Received: January 12, 2017 Last Updated: January 24, 2017 Estimated Primary Completion Date: July 2016 Primary Outcome Measures: Blood loss|Red blood cell count|White blood cell count|Platelet count|Fibrinogen levels|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (aPTT)|Endogenous Thrombin Potential (Thrombin generation assay (CAT))|Lag Time (Thrombin generation assay (CAT))|Time-to-Thrombin Peak (Thrombin generation assay (CAT))|Thrombin Peak (TP) (Thrombin generation assay (CAT))|P-selectin expression (Platelet activation test (PACT))|αIIbβ3 activation (Platelet activation test (PACT))|A5 EXTEM (Rotational thromboelastometry (ROTEM))|A5 FIBTEM (Rotational thromboelastometry (ROTEM))|A5 HEPTEM...

Continue reading

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Condition Lung Cancer|Malignant Mesothelioma|Metastatic Cancer|Thymoma and Thymic Carcinoma Estimated Enrollment: 30 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000068889|P30CA016042|UCLA-9908024|NCI-G01-2011 Study First Received: September 13, 2001 Last Updated: October 28, 2015 Estimated Primary Completion Date: December 2006 Primary Outcome Measures: Sponsors and Collaborators: Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00024076...

Continue reading

Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)

Condition Metastatic Non-squamous Non Small Cell Lung Cancer Estimated Enrollment: 201 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CBP08-02 Study First Received: July 17, 2009 Last Updated: July 29, 2013 Estimated Primary Completion Date: July 2013 Primary Outcome Measures: The primary efficacy endpoint is Progression free survival, analyzed in the treated population. PFS is assessed from randomization until either tumor progression, as per RECIST criteria, or until death due to any reason.|Objective response rate (CR + PR): response is to be assessed according to RECIST criteria (see Section 7.1), with...

Continue reading